Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: methocarbamol, dichlorphenamide, polmacoxib +5 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 333 Parkinson's papers of 33,731 | 0.23 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 11157
Sealed predictions
- CA1 in dopamine neurons, braak+0.12 (p 0.753) → +0.58 (p 0.102)receipt 11163
Swarm cases
receipt 11163: CA1 in dopamine neurons, braak
- power
- full sample +0.31 (p 0.214, n 18), 95% CI -0.19 to +0.68. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.235, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.235, n 18). could be the mix.
- skeptic
- leave-one-out range +0.21 to +0.41, sign flips 0; without severely affected donors +0.31 (p 0.214, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CA1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts